Sign in

    Daniel Biolsi

    Research Analyst at Hedgeye Risk Management

    Daniel Biolsi is Managing Director and Head of Consumer Staples Research at Hedgeye Risk Management, specializing in deep fundamental and quantitative analysis across consumer sectors. He covers major companies such as Dollar Tree, supermarkets, restaurants, food distributors, beverage firms, and cannabis operators, and has delivered actionable long and short recommendations for institutional clients, generating consistent positive returns. With over twenty years of analyst experience including broad coverage in retail, food & beverage, and airlines, Biolsi has been at Hedgeye since the firm's founding period, where he became recognized for insightful sector calls featured on platforms like The Call @ Hedgeye. His professional credentials include extensive investment management experience; however, public disclosures do not indicate FINRA registration or specific securities licenses.

    Daniel Biolsi's questions to BRC (BRCC) leadership

    Daniel Biolsi's questions to BRC (BRCC) leadership • Q2 2025

    Question

    Daniel Biolsi of Hedgeye Risk Management, LLC asked for the price versus volume breakdown of the 14% wholesale growth. He also inquired about the biggest swing factors expected to drive the significant adjusted EBITDA increase from the first half to the second half of the year.

    Answer

    CFO Matthew Amigh clarified that the 14% wholesale growth was 100% driven by volume, as pricing actions did not take effect until Q3. For the back-half EBITDA ramp, Amigh detailed several drivers: sequential revenue step-ups from distribution gains and seasonality, the impact of Q3/Q4 pricing actions, lower slotting fees, maturing operational efficiencies, and a modest decrease in marketing spend.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to BRC (BRCC) leadership • Q1 2025

    Question

    Daniel Biolsi sought to clarify the components of the gross margin impact, asking how much of the trade and price investment was due to energy drink slotting fees and about the lag time for tariffs to affect the cost of goods sold.

    Answer

    CFO Steve Kadenacy confirmed that the trade and slotting fee impact was almost entirely related to the energy drink launch. He also clarified that the 90-day figure mentioned earlier referred to competitors' hedging positions, not BRCC's inventory lag, and that tariffs are expected to primarily impact COGS starting in the third quarter.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to BRC (BRCC) leadership • Q4 2024

    Question

    Daniel Biolsi questioned the company's plans for price increases on bagged coffee in light of green coffee inflation, and asked about the volume of energy drinks shipped in Q4 and the timing of associated slotting fees.

    Answer

    Head of IR Matt McGinley stated that Black Rifle is a price follower and is monitoring competitor price hikes. He confirmed no price increases are currently factored into 2025 guidance, meaning any future increases would represent upside. CEO Chris Mondzelewski noted that some energy drinks were shipped in Q4, but the volume and associated costs were all anticipated and built into the 2025 plan. McGinley added that trade promotion costs are expected to be more weighted to the first half of the year.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to SunOpta (STKL) leadership

    Daniel Biolsi's questions to SunOpta (STKL) leadership • Q1 2025

    Question

    Daniel Biolsi inquired about the outlook for raw material costs and pricing for the year, and also asked about the strategy behind the new share repurchase authorization, questioning if it was opportunistic.

    Answer

    Executive Greg Gaba stated that excluding tariffs, he expects no major changes in raw material costs, with pricing impact likely remaining in a low single-digit range similar to Q1. Executive Brian Kocher confirmed the share repurchase plan is opportunistic. The top priority remains deleveraging to under 2.5x, but with no growth CapEx needed in 2025, the authorization provides a tool to return capital if the company is ahead of its deleveraging plan.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to SunOpta (STKL) leadership • Q4 2024

    Question

    Daniel Biolsi asked how long the company can meet demand in its capacity-constrained fruit snacks business before needing new capital, and what to expect for inflation and pricing in the plant-based segment for 2025.

    Answer

    CEO Brian Kocher acknowledged that the fruit snacks business is tighter on capacity than plant-based, but they are still finding efficiencies to increase output. CFO Greg Gaba stated that while some commodity costs have risen, contract structures allow for pass-throughs, and he does not expect a material impact to the bottom line, confirming the 7-11% revenue growth is volume-driven.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to SunOpta (STKL) leadership • Q2 2024

    Question

    Daniel Biolsi from Hedgeye Risk Management inquired about the growth trends across different types of plant-based milks and asked about the company's capital allocation priorities, specifically comparing CapEx versus share repurchases, after reaching its leverage target.

    Answer

    Executive Brian Kocher stated that the secular trends across different plant-based milk types remain consistent and that the company's strength lies in offering a full spectrum of options to its customers. Regarding capital allocation, Kocher stressed that the immediate focus is on execution and deleveraging to under 3x. Once that goal is achieved, returning capital to shareholders will be a top consideration, alongside other relative investment opportunities, but he declined to commit to a specific strategy at this time.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to PERRIGO Co (PRGO) leadership

    Daniel Biolsi's questions to PERRIGO Co (PRGO) leadership • Q1 2025

    Question

    Daniel Biolsi asked about the risk of lower fall sales for upper respiratory products after a late cold season and inquired about the status of the inventory rebuild and on-shelf availability for the nutrition category.

    Answer

    CEO Patrick Lockwood-Taylor saw no data suggesting a destocking risk in upper respiratory, highlighting that Perrigo's domestic manufacturing provides agility. He confirmed that nutrition on-shelf availability is at 'going levels' and will be further strengthened by a 'second big distribution surge' from the introduction of 60 new SKUs in the coming months.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to PERRIGO Co (PRGO) leadership • Q3 2024

    Question

    Daniel Biolsi asked about the price gap between national and store brands and whether the innovation pipeline is returning to normal levels post-pandemic.

    Answer

    CFO Eduardo Bezerra noted that while the price gap had widened, national brands are now using more promotions, potentially narrowing it. CEO Patrick Lockwood-Taylor added that store brand volume share is growing and retailers are investing more in demand creation. He also explained that Perrigo is revamping its innovation strategy to focus on fewer, larger, and more scalable projects with higher NPVs, which will be detailed further in February.

    Ask Fintool Equity Research AI

    Daniel Biolsi's questions to PERRIGO Co (PRGO) leadership • Q2 2024

    Question

    Daniel Biolsi from Hedgeye asked about the infant formula business, specifically regarding any loss of shelf space and the timeline for rebuilding safety stock. He also questioned the company's inventory strategy for phenylephrine products given potential FDA action, and whether lower retailer inventories for cough/cold products require Perrigo to hold more stock.

    Answer

    CFO Eduardo Bezerra stated that rebuilding infant formula safety stock is challenging due to high demand and is more likely to occur in the first half of 2025. CEO Patrick Lockwood-Taylor addressed phenylephrine, stating there are no plans to reduce inventory as demand continues and a shift to other formulations could be positive. Bezerra characterized the retailer inventory destocking for cough/cold as a one-time normalization, suggesting a potential need for replenishment in H2.

    Ask Fintool Equity Research AI